



FRENCH AGENCY FOR VETERINARY MEDICINAL PRODUCTS
La Haute Marche
Javené BP 90203
35302 FOUGERES cedex
FRANCE

DECENTRALISED PROCEDURE

**PUBLICLY AVAILABLE ASSESSMENT REPORT
FOR A VETERINARY MEDICINAL PRODUCT**

Wellicox 50 mg/ml solution for injection for cattle, pigs and horses

Date: 25/02/2013

MODULE 1

PRODUCT SUMMARY

EU Procedure number	FR/V/0241/001/DC
Name, strength and pharmaceutical form	Wellicox 50 mg/ml solution for injection for cattle, pigs and horses Solution for injection.
Applicant	COOPHAVET 23, Rue du Prieuré Saint Herblon 44150 Ancenis FRANCE
Active substance(s)	Flunixin (as meglumine)
ATC Vetcode	QM01AG90
Target species	Cattle, pigs and horses.
Indication for use	<p>Cattle:</p> <ul style="list-style-type: none"> - Alleviation of clinical signs when respiratory disease concurrently with appropriate anti-infective therapy. <p>Pigs:</p> <ul style="list-style-type: none"> - To support appropriate antibiotic therapy in the treatment of Mastitis-Metritis-Agalactia syndrome. - Alleviation of fever associated with respiratory diseases as an adjunctive therapy to specific antibiotic therapy. <p>Horses:</p> <ul style="list-style-type: none"> - Alleviation of inflammation and pain associated with musculo-skeletal disorders. - Alleviation of visceral pain associated with colic.

MODULE 2

The Summary of Product Characteristics (SPC) for this product is available on the website <http://www.anmv.anses.fr/>

MODULE 3

PUBLIC ASSESSMENT REPORT

Legal basis of original application	Generic application in accordance with Article 13 (1) of Directive 2001/82/EC as amended.
Date of completion of the original decentralised procedure	04/02/2013

I. SCIENTIFIC OVERVIEW

The product is produced and controlled using validated methods and tests, which ensure the consistency of the product released on the market.

It has been shown that the product can be safely used in the target species; the slight reactions observed are indicated in the SPC.

The product is safe for the user, the consumer of foodstuffs from treated animals and for the environment, when used as recommended. Suitable warnings and precautions are indicated in the SPC.

The efficacy of the product was demonstrated according to the claims made in the SPC.

The overall risk/benefit analysis is in favour of granting a marketing authorisation.

II. QUALITY ASPECTS

A. Composition

The product contains 50 mg/ml flunixin meglumine and excipients phenol, sodium formaldehyde sulfoxylate, disodium edetate, diethanolamine, propylene glycol, dilute hydrochloric acid, water for injections.

The container is a glass or polyethylene terephthalate bottle closed with rubber stopper. The particulars of the containers and controls performed are provided and conform to the regulation.

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

B. Method of Preparation of the Product

The product is manufactured fully in accordance with the principles of good manufacturing practice from a licensed manufacturing site.

Process validation data on the product have been presented in accordance with the relevant European guidelines.

C. Control of Starting Materials

The active substance is flunixin meglumine, an established substance described in the European Pharmacopoeia. The active substance is manufactured in accordance with the principles of good manufacturing practice.

The active substance specification is considered adequate to control the quality of the material. Batch analytical data demonstrating compliance with this specification have been provided.

D. Specific Measures concerning the Prevention of the Transmission of Animal Spongiform Encephalopathies

There are no substances within the scope of the TSE Guideline present or used in the manufacture of this product.

E. Control on intermediate products

Not applicable.

F. Control Tests on the Finished Product

The finished product specification controls the relevant parameters for the pharmaceutical form. The tests in the specification, and their limits, have been justified and are considered appropriate to adequately control the quality of the product.

Satisfactory validation data for the analytical methods have been provided.

Batch analytical data from the proposed production site have been provided demonstrating compliance with the specification.

G. Stability

Stability data on the active substance have been provided in accordance with applicable European guidelines, demonstrating the stability of the active substance when stored under the approved conditions.

Stability data on the finished product have been provided in accordance with applicable European guidelines, demonstrating the stability of the product throughout its shelf life when stored under the approved conditions.

An in-use shelf-life as details on the SPC has been supported by appropriate data.

H. Genetically Modified Organisms

Not applicable

J. Other Information

Not applicable

III. SAFETY AND RESIDUES ASSESSMENT (PHARMACO-TOXICOLOGICAL)

III.A Safety Testing

Pharmacological Studies

The test product is bioequivalent to the reference product FINADYNE, marketed by INTERVET. Bioequivalence studies were supplied for bovine and pig species. An exemption from the requirement to provide bioequivalence studies was accepted for horses as

bioequivalence was demonstrated in two major species and formulations of the tested and the reference products were similar..

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of pharmacological tests are not required.

The pharmacological aspects of this product are identical to the reference product.

Toxicological Studies

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, results of toxicological tests are not required.

The toxicological aspects of this product are identical to the reference product.

User Safety

The applicant has provided a user safety assessment in compliance with the relevant guideline. Moreover, the formulations of the tested and the reference products are similar.

Warnings and precautions as listed on the product literature are adequate to ensure safety to users of the product.

Ecotoxicity

The applicant has provided a first phase environmental risk assessment in compliance with the relevant guideline which showed that no further assessment is required.

III.B Residues documentation

Residue Studies

GLP Residues studies were submitted in pigs and cattle. These studies only investigated residues at injection sites.

MRLs**a. active substances**

The active substance is included in table 1 of the MRL regulation 470/2009, as follows:

FLUNIXIN						
Marker residue	Animal Species	MRL	Target Tissues	Other Provisions	Therapeutic Classification	Regulation
flunixin	Bovine	20 µg/kg 30 µg/kg 300 µg/kg 100 µg/kg	Muscle Fat Liver Kidney	No entry	Anti-inflammatory agents/ Nonsteroidal anti-inflammatory agents	37/2010 of 22.12.2009
	Porcine	50 µg/kg 10 µg/kg 200 µg/kg 30 µg/kg	Muscle Skin + fat Liver Kidney			
	<i>Equidae</i>	10 µg/kg 20 µg/kg 100 µg/kg 200 µg/kg	Muscle Fat Liver Kidney			
5-hydroxyflunixin	Bovine	40 µg/kg	Milk			

b. excipients

The MRL status of excipients of the product is indicated in the following table.

Excipient	MRL status	ADI
Phenol	Table 1, no MRL required	-
Sodium formaldehyde sulfoxylate	Table 1, no MRL required	-
Disodium edetate	Table 1, no MRL required	-
Diethanolamine	Out of scope	
Propylene glycol	Table 1, no MRL required	-
Dilute hydrochloric acid	Table 1, no MRL required	-
Water for injections	Out of scope	

Withdrawal Periods

Based on the data provided above, and considering that the tested product and reference product have similar formulations and are recommended for use at the same posology and route of administration, the reference product withdrawal periods are applied to the tested product:

Cattle:

Meat and offal: 10 days.

Milk: 24 hours.

Pigs:

Meat and offal: 20 days.

Horses:

Meat and offal: 10 days.

Milk: the product is not authorised for use in lactating animals producing milk for human consumption.

IV. CLINICAL ASSESSMENT (EFFICACY)

IV.A Pre-Clinical Studies

Tolerance in the Target Species of Animals

The applicant has not provided tolerance study which is acceptable because the tested product and the reference product are bioequivalent, have similar formulations and are recommended for use at the same posology and route of administration.

The tolerance aspects of this product are identical to the reference product. Based on the conclusion made for the reference product, the product literature accurately reflects the type and incidence of adverse effects which might be expected.

IV.B Clinical Studies

As this is a generic application according to Article 13, and bioequivalence with a reference product has been demonstrated, efficacy studies are not required. The efficacy claims for this product are equivalent to those of the reference product.

V. OVERALL CONCLUSION AND BENEFIT– RISK ASSESSMENT

The data submitted in the dossier demonstrate that when the product is used in accordance with the Summary of Product Characteristics, the risk benefit profile for the target species is favourable and the quality and safety of the product for humans and the environment is acceptable.